Pfizer authorizes $1 billion for oral COVID-19 treatment, CEO says

Pfizer (PFE) CEO Albert Bourla is betting massive on repeating the accomplishment of its COVID-19 vaccine with an experimental oral remedy — and he is putting the firm’s money wherever its mouth is.

Bourla explained to Yahoo Finance Wednesday the firm is committing $1 billion to build the oral remedy — a protease inhibitor — which would give the world an uncomplicated-to-use, focused remedy, ideally by year’s stop.

The latest sector for COVID-19 remedies features monoclonal antibodies and some repurposed medications, which include generics and Gilead Sciences’ (GILD) Veklury (previously Remdesivir) – all of which require currently being in a

Read more